Hinge Health price target raised to $63 from $55 at Stifel

Stifel analyst David Grossman raised the firm’s price target on Hinge Health (HNGE) to $63 from $55 and keeps a Buy rating on the shares. Q2 results “materially outperformed” consensus and 2025 guidance for revenue and EBIT were raised “materially above our street high estimate,” the analyst tells investors. The firm maintains its 2026 revenue growth estimate at about 20%, but increased its EBIT margin assumption to 17% from 10.5%, reflecting leverage from higher revenue and modestly higher yields, the analyst added.